Israel - hebreiska - Ministry of Health

teva pharmaceutical industries ltd, israel - duloxetine as hydrochloride - קפסולות - duloxetine as hydrochloride 60 mg - duloxetine

Israel - hebreiska - Ministry of Health

teva pharmaceutical industries ltd, israel - duloxetine as hydrochloride - קפסולות - duloxetine as hydrochloride 30 mg - duloxetine

Israel - hebreiska - Ministry of Health

eli lilly israel ltd, israel - duloxetine as hydrochloride - duloxetine as hydrochloride 30 mg - duloxetine

Israel - hebreiska - Ministry of Health

eli lilly israel ltd, israel - duloxetine as hydrochloride - duloxetine as hydrochloride 60 mg - duloxetine

Israel - hebreiska - Ministry of Health

abic marketing ltd, israel - duloxetine as hydrochloride - duloxetine as hydrochloride 30 mg - duloxetine

Israel - hebreiska - Ministry of Health

abic marketing ltd, israel - duloxetine as hydrochloride - duloxetine as hydrochloride 60 mg - duloxetine

Israel - hebreiska - Ministry of Health

novartis israel ltd - duloxetine as hydrochloride - duloxetine as hydrochloride 30 mg - duloxetine

Israel - hebreiska - Ministry of Health

novartis israel ltd - duloxetine as hydrochloride - duloxetine as hydrochloride 60 mg - duloxetine

Israel - hebreiska - Ministry of Health

sanofi israel ltd - thyrotropin alfa - אבקה להכנת תמיסה לזריקה - thyrotropin alfa 0.9 mg/ml - thyrotropin - thyrotropin - adjunctive diagnostic tool for serum thyroglobulin (tg) testing with or without radioiodine imaging in the followup of patients with well-differentiated thyroid cancer.adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well differentiated thyroid cancer and who do not have evidence of metastatic thyroid cancer.

Israel - hebreiska - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - eptifibatide - תמיסה לאינפוזיה - eptifibatide 0.75 mg/ml - eptifibatide - eptifibatide - integrilin is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. integrilin is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). integrilin is intended for use with aspirin and heparin.